Lachlan Brown
Stock Analyst at William Blair
(1.10)
# 3,394
Out of 5,180 analysts
12
Total ratings
33.33%
Success rate
-0.06%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Initiates: Outperform | n/a | $7.24 | - | 1 | Mar 23, 2026 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | n/a | $19.56 | - | 1 | Dec 3, 2025 | |
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $133.12 | +50.24% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $35.26 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $5.77 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $8.47 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $396.48 | +51.33% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $277.87 | +25.96% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $40.23 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $71.56 | +25.77% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $220 | $55.67 | +295.19% | 1 | May 14, 2024 |
Eupraxia Pharmaceuticals
Mar 23, 2026
Initiates: Outperform
Price Target: n/a
Current: $7.24
Upside: -
Viridian Therapeutics
Dec 3, 2025
Initiates: Outperform
Price Target: n/a
Current: $19.56
Upside: -
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $133.12
Upside: +50.24%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $35.26
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $5.77
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.47
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $396.48
Upside: +51.33%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $277.87
Upside: +25.96%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $40.23
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $71.56
Upside: +25.77%
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $55.67
Upside: +295.19%